Evaluating self-sampling versus clinician-sampling for HPV testing in cervical cancer screening
Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings
NA · National Healthcare Group Polyclinics · NCT06528184
This study is testing if self-sampling for HPV testing can find more cases of high-risk HPV compared to traditional testing done by a doctor, to see if it could be a better option for cervical cancer screening.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 650 (estimated) |
| Ages | 30 Years to 69 Years |
| Sex | Female |
| Sponsor | National Healthcare Group Polyclinics (other gov) |
| Locations | 1 site (Singapore, Singapore) |
| Trial ID | NCT06528184 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effectiveness of self-sampling for HPV DNA testing compared to traditional clinician-sampling in primary care settings. It is a multi-center, randomized controlled trial where participants will be offered either clinician-sampling or, if declined, self-sampling for HPV testing. The primary goal is to determine if self-sampling increases the detection rates of high-risk HPV DNA by at least 7.7%. The findings will provide insights into the feasibility and cost-effectiveness of implementing self-sampling in routine cervical cancer screening.
Who should consider this trial
Good fit: Ideal candidates are females aged 30-69 who are due for cervical cancer screening and have previously engaged in sexual intercourse.
Not a fit: Patients who are virgins, pregnant, or have a history of cervical cancer or total hysterectomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to higher detection rates of HPV, improving early diagnosis and treatment of cervical cancer.
How similar studies have performed: Other studies have shown promising results with self-sampling approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 30-69 years old female Singapore citizens * Due for cervical cancer screening * Engaged in sexual intercourse before * Able to give informed consent * Able to read and communicate in English, Chinese or Malay Exclusion Criteria: * Virgo intacta * Pregnancy * History of cervical cancer, precancerous cervical lesions and total hysterectomy
Where this trial is running
Singapore, Singapore
- National Healthcare Group Polyclinics — Singapore, Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Ng Xin Rong, MBBS — National Healthcare Group Polyclinics
- Study coordinator: Ng Xin Rong, MBBS
- Email: xin_rong_ng@nhgp.com.sg
- Phone: +65 63553000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Uterine Cervical Neoplasms